Cannabis and antidepressants – can antidepressants be combined with CBD and marijuana?

Cannabis and antidepressants are one of the most frequently asked and pharmacologically risky pairs in psychiatrists' offices. According to data from the National Health Fund, in 2023, over 15.8 million packages of antidepressants were dispensed in Poland, and the estimated number of CBD users exceeded 900 thousand people (NFZ, 2023). The population using both groups of substances is growing year by year. The problem is that CBD and THC interact in measurable, sometimes dangerous ways with sertraline, escitalopram, citalopram, fluoxetine, venlafaxine, amitriptyline, and monoamine oxidase inhibitors. In this article, we break down pharmacokinetics (what the liver does to the drug), pharmacodynamics (what happens at the synapse), the mechanism of serotonin syndrome, cardiovascular risks, and specific recommendations for patients in the Polish context.

The article was prepared by Michał Waluk based on peer-reviewed medical publications (Vaughn et al. 2021 Journal of Personalized Medicine; Brown and Winterstein 2019 Journal of Clinical Medicine; Bansal et al. 2020 British Journal of Clinical Pharmacology; Cochrane meta-analyses, FAERS reports, NICE guidelines, Polish Psychiatric Association, and Frontiers in Pharmacology).

/cbd-czy-pomaga-w-leczeniu-depresji/

Can cannabis be combined with antidepressants?

There is no simple yes or no answer, and the default recommendation is: not without psychiatric supervision. According to a review in the "British Journal of Clinical Pharmacology" (Bansal et al., 2020) CBD has potential interactions with over 60 prescription drugs, of which 12 classes of antidepressants are on the high-risk list.

Depression in Poland affects about 4 million people, and according to a report from the Institute of Psychiatry and Neurology (2022), only one in three people with clinical depression receives appropriate pharmacological treatment. In this therapeutic gap, CBD supplements, hemp oils, CBD flower, and medical marijuana emerge. Patients often turn to cannabis on their own, without informing their psychiatrist, creating a dangerous gray area.

In response to the question "can they be combined," the clinical answer is three-tiered. First, at small doses of CBD (up to 25 mg/day orally), interaction with most SSRIs is clinically insignificant in healthy adults. Second, at therapeutic doses (100-600 mg/day), CYP450 inhibition is measurable and may require a reduction in the antidepressant dose. Third, simultaneous smoking or vaporization of marijuana with high THC alters both the drug's metabolism and its action on serotonin, making this combination difficult to control.

When is the risk highest?

The risk increases exponentially in five scenarios. First, with older drugs that have a narrow therapeutic index (tricyclic antidepressants like amitriptyline, clomipramine, and MAO inhibitors like moclobemide, selegiline). Second, in patients with bipolar disorder, where THC may trigger a manic episode. Third, with polypharmacy (simultaneously taking 3+ psychotropic drugs). Fourth, in older individuals and those with liver failure. Fifth, with high doses of CBD (above 300 mg/day) or daily THC vaporization.

In Polish clinical practice, the biggest problem does not concern patients consciously combining substances. The most therapeutic failures occur in individuals who started supplementing CBD believing it to be a "natural cosmetic" and did not mention it to their psychiatrist. The result: unexplained excessive sedation, nausea, or lack of response to a previously well-chosen medication.

How do antidepressants work at the neurochemical level?

Antidepressants increase the availability of neurotransmitters in the brain synapses, primarily serotonin, norepinephrine, and dopamine. According to the NICE report from 2022, a full clinical response appears only after 4-6 weeks of treatment, and in 30-40% of patients, the first medication proves ineffective and requires switching (NICE NG222, 2022).

SSRIs, or selective serotonin reuptake inhibitors

The SSRI group includes sertraline, escitalopram, citalopram, fluoxetine, paroxetine, and fluvoxamine. The mechanism of action involves blocking the serotonin transporter (SERT) in the presynaptic membrane. Serotonin remains longer in the synaptic cleft and more strongly stimulates the postsynaptic 5-HT1A and 5-HT2A receptors. In Poland, SSRIs account for over 65% of all prescriptions for antidepressants.

Among SSRIs, the greatest metabolic variability concerns liver enzymes. Sertraline is primarily metabolized by CYP2B6, CYP2C19, and CYP3A4. Escitalopram and citalopram pass through CYP2C19, CYP3A4, and CYP2D6. Fluoxetine is itself an inhibitor of CYP2D6, which already makes it the "most demanding" SSRI in polypharmacy without additional CBD.

SNRIs, TCAs, and MAOIs

Serotonin-norepinephrine reuptake inhibitors (SNRIs, e.g., venlafaxine, duloxetine, desvenlafaxine) block both SERT and NET simultaneously. Classic tricyclic antidepressants (TCAs, e.g., amitriptyline, clomipramine, nortriptyline, doxepin) act broadly on many systems, including serotoninergic, noradrenergic, muscarinic, and histaminergic. Monoamine oxidase inhibitors (MAOIs, moclobemide, selegiline, tranylcypromine) inhibit the enzyme that breaks down monoamines.

TCAs and MAOIs have the narrowest therapeutic index, meaning the difference between the effective and toxic dose is small. Adding CBD, which inhibits their metabolism, can quickly shift the concentration into the toxic range. Moreover, MAOIs combined with THC or CBD carry a historical risk of hypertensive crisis and serotonin syndrome, which is why in psychiatric practice in Poland, MAOI + cannabis is an absolute contraindication.

Newer molecules: bupropion, mirtazapine, vortioxetine

Bupropion (norepinephrine-dopamine reuptake inhibitor, NDRI) is metabolized by CYP2B6 to hydroxybupropion. CBD has a weak effect on CYP2B6, so pharmacokinetically this combination is relatively safe, but bupropion lowers the seizure threshold, and high doses of THC may further lower this threshold. Mirtazapine (NaSSA receptor antagonist) is primarily metabolized by CYP3A4, CYP2D6, and CYP1A2. Vortioxetine (multimodal serotoninergic modulator) mainly passes through CYP2D6.

In each of these cases, there is a specific metabolic pathway that CBD can block. For the patient, this means one thing: there is no "safe" antidepressant that would not require a conversation with a doctor before adding cannabidiol.

How does CBD inhibit cytochrome P450 and change the concentration of antidepressants?

CBD is one of the stronger plant inhibitors of cytochrome P450 known in pharmacology. A study by Vaughn et al. published in the "Journal of Personalized Medicine" in 2021 showed that adding CBD to therapy with escitalopram or sertraline increases the maximum concentration of the drug (C_max) by 25-26% and the area under the curve (AUC) by 33-35% in adolescents with depressive disorders (PMC, 2021).

The mechanism of inhibiting liver enzymes

Cytochrome P450 is a family of enzymes in the liver responsible for the metabolism of over 75% of all prescription drugs. CBD interacts with them in two ways. First, it binds to the active site of the enzyme, blocking access to other molecules. Second, with long-term use, it induces or suppresses the expression of genes encoding these enzymes.

Key isoforms inhibited by CBD are CYP3A4 (responsible for 50% of drug metabolism), CYP2D6 (metabolizes most antidepressants), CYP2C19 (escitalopram, citalopram, sertraline), and CYP2C9. Inhibition is dose-dependent. At cosmetic doses (5-15 mg CBD), the effect is minimal. At therapeutic doses, such as those used in Epidiolex for children with epilepsy (10-20 mg/kg/day), the blockade of CYP3A4 and CYP2C19 is strong and comparable to ketoconazole or fluvoxamine.

What happens when the concentration of SSRIs increases?

Higher concentrations of sertraline, escitalopram, citalopram, or fluoxetine in plasma result in an intensification of expected adverse effects. The most common are nausea, diarrhea, headache, insomnia, muscle tremors, excessive sweating, sexual dysfunction, and sedation. In extreme cases, serotonin syndrome may occur.

Serotonin syndrome is a life-threatening condition. Symptoms: tachycardia, hypertension, hyperthermia (above 38°C), muscle tremors, rigidity, myoclonus, agitation, disorientation, dilated pupils. If untreated, it leads to multiple organ failure. The risk increases when combining two serotoninergic substances, and high doses of CBD may act as an additional modulator of 5-HT1A.

Smoking marijuana and CYP1A2 induction

Smoking both tobacco and hemp flower induces the CYP1A2 enzyme, thus accelerating its synthesis. This mechanism is the opposite of CBD inhibition. A patient who regularly smokes hemp flower may metabolize some medications (e.g., duloxetine, clozapine, olanzapine, mirtazapine in part) faster and achieve lower therapeutic concentrations. Clinical effect: the drug "stops working," and the psychiatrist, unaware of the smoking, increases the dose.

In conversations with patients, we observe a characteristic pattern. A person taking escitalopram feels well for 3-4 months. They start vaporizing medical marijuana on the recommendation of another doctor (e.g., for pain relief). After 2-3 weeks, apathy, nausea, and drowsiness appear. The culprit is the increased concentration of escitalopram, not depression. The solution is not to increase the SSRI dose but to reduce the CBD/THC dose and assess the condition with the psychiatrist.

What are the pharmacodynamic interactions of cannabis with antidepressants?

Pharmacodynamics describes how substances act on the same receptors or neurochemical systems. According to a review in "Frontiers in Pharmacology" (2023), CBD interacts with the serotonin receptor 5-HT1A as an agonist, which in theory may complement the action of SSRIs, but in practice accumulates the risk of serotonin syndrome (Frontiers in Pharmacology, 2023).

CBD and the serotonin receptor 5-HT1A

Cannabidiol binds to the 5-HT1A receptor with moderate affinity. This receptor controls anxiety, mood, and stress response. Paradoxically, it is the same receptor through which buspirone exerts its anxiolytic effect, and partially also newer drugs like vortioxetine. When a patient takes SSRIs (increasing serotonin) and adds CBD (stimulating 5-HT1A), the total serotonergic activation may exceed the safety threshold.

At low doses of CBD (up to 50 mg), the effect is subtle. At clinical doses (300-800 mg, used in studies on treatment-resistant epilepsy), the stimulation of 5-HT1A becomes clinically significant. Patients with a well-adjusted dose of sertraline or escitalopram, adding high-dose CBD, may experience intensified nausea, tremors, and insomnia typical of too high a dose of SSRIs.

THC and CB1 receptors and dopaminergic modulation

Tetrahydrocannabinol binds to cannabinoid receptors CB1 in the prefrontal cortex, hippocampus, amygdala, and striatum. Activation of CB1 increases dopamine release in the mesolimbic pathway, which in healthy individuals produces an euphoric effect, while in those with a predisposition to psychosis – symptoms of dissociation, paranoia, and anxiety.

In patients taking SSRIs or SNRIs, THC alters the dopamine-serotonin balance. In some individuals, it exacerbates anxiety even despite the increasing anxiolytic effect of SSRIs. In individuals with bipolar affective disorder in remission, THC can 'disassemble' the mood stabilizer and trigger a manic or hypomanic episode.

Anandamide and endocannabinoids in depression

Endocannabinoids, primarily anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are produced by our brain and modulate mood, memory, and stress response. Individuals with depression have lower levels of AEA in serum than healthy individuals, which has been the subject of many studies by Hill and Gorzalka in the last decade. CBD inhibits the FAAH enzyme that breaks down AEA, indirectly raising endogenous cannabinoid signaling.

Theoretically, this property of CBD could support the action of SSRIs on the HPA axis (hypothalamic-pituitary-adrenal). In practice, data from randomized clinical trials are scarce and contradictory. No large RCT has yet shown that adding CBD to SSRIs accelerates depression remission in a statistically significant way. Until such a study appears, CBD remains a pharmacological curiosity, not an augmentation of the standard treatment.

/jak-cbd-i-inne-kannabinoidy-konopne-dzialaja-na-organizm-czlowieka/

What do scientific studies say about combining CBD and marijuana with SSRIs?

The evidence base is limited and uneven. According to an analysis of data from the FDA Adverse Event Reporting System (FAERS) from 2023, among 21 million reports concerning SSRIs, 3,678 cases of co-administration with cannabinoids were identified, of which 30% resulted in serious adverse effects requiring hospitalization (FDA FAERS, 2023).

The study by Vaughn et al. (2021)

The key study by Vaughn et al. from the University of Minnesota included 8 adolescents taking SSRIs and using cannabis products. Although the sample is small, the methodology (measuring drug levels in serum before and after adding CBD or THC) provides strong pharmacokinetic evidence. All participants showed an increase in C_max and AUC of escitalopram and sertraline, and in some, an extension of the half-life by up to 40%.

Meta-analysis by Brown and Winterstein (2019)

Brown and Winterstein in 'Journal of Clinical Medicine' (2019) analyzed 139 clinical and preclinical studies regarding CBD interactions with medications. Among antidepressants, the highest risk of interactions was attributed to fluoxetine, fluvoxamine, clomipramine, and amitriptyline. The authors recommended monitoring clinical symptoms and considering measuring drug concentration in the blood for patients taking CBD at doses above 100 mg daily.

FAERS analysis and real adverse effects

The analysis of data from FAERS allows us to see which adverse effects appear disproportionately when co-administering SSRIs and cannabinoids. Here is the risk scale compared to SSRIs alone (odds ratio):

Adverse reaction	Risk increase (fold)	Mechanism
Cough	4.97x	Irritation of the respiratory tract by smoke
Diarrhea	3.33x	Higher SSRI concentration in the intestines
Fatigue and sedation	3.29x	Synergy of CBD and SSRIs
Dizziness	2.87x	Lowered blood pressure, central effect
Serotonin syndrome	2.45x	Cumulative signal 5-HT1A/5-HT2A
Prolonged QTc	1.92x	CBD + citalopram, inhibition of CYP2C19

Randomized studies on CBD in depression

Frontiers in Psychiatry (2021) described a self-reported study on a population of 538 individuals using medical marijuana. In 67% of participants, a reduction in depressive symptoms was reported, but the method relied on self-assessment and did not control for concurrent pharmacotherapy. This is a typical problem with naturalistic studies: the placebo effect, expectations, and lack of blinding give the results limited value for evidence-based medicine.

Five randomized clinical trials of CBD in depression published by 2024 yielded conflicting results. Two showed a slight antidepressant effect at a dose of 300 mg/day, two found no difference from placebo, and one showed improvement only in a subgroup with high comorbid anxiety. Cochrane in a 2023 review classified the evidence as 'low quality, insufficient for clinical recommendation.'

When can cannabis help, and when can it harm in depression?

The line between potential benefit and harm runs through the specific patient profile and dose. According to the report from the Polish Psychiatric Association in 2024, medical marijuana remains a last-resort drug for resistant cancer pain, spasticity, and nausea after chemotherapy, not for depression as such.

Situations where CBD may be considered as support

There are clinical scenarios where a psychiatrist may, after considering the risks, accept the addition of low doses of CBD to treatment. The list is short.

• A patient with depression and accompanying generalized anxiety, stable on a low dose of SSRI. CBD 25-50 mg/day may support the anxiolytic effect. Requires clinical assessment every 4 weeks.
• A patient with depression and primary insomnia. Evening CBD at a dose of 25-75 mg shortens sleep latency. It should be monitored to see if it increases morning sedation.
• A patient with depression and chronic pain. Broad-spectrum CBD oil may assist in pain control. Less risk than opioids.
• A patient in remission from depression, without an active episode. CBD as a supplement during occasional stress may be safe with careful monitoring.

Situations where cannabis is contraindicated

The list of contraindications is longer and more categorical. In these situations, no doses of CBD, THC, or cannabis flower should be used without very strong clinical justification.

• Bipolar disorder. THC may trigger a manic, hypomanic, or mixed episode.
• Schizophrenia or a history of a psychotic episode. THC increases the risk of psychosis recurrence by 2-4 times (Lancet Psychiatry, 2019).
• Pregnancy and breastfeeding. CBD and THC cross the placenta and into breast milk, posing a risk of developmental failures.
• Treatment with MAO inhibitors (moclobemide, selegiline, tranylcypromine). Risk of hypertensive crisis.
• Recent suicide attempt or active suicidal thoughts. THC may increase impulsivity and disinhibition.
• Severe liver diseases (Child-Pugh B or C). Metabolism limitation, accumulation of CBD and medications.
• Children and adolescents under 18 years of age (except for treatment-resistant epilepsy). Immature brain, high risk of lasting effects from THC.

A special case: marijuana in individuals with bipolar disorder

Bipolar disorder is one of the key controversies. Cerullo and Strakowski in 'Harvard Review of Psychiatry' (2020) documented that in patients with bipolar disorder who regularly use marijuana, manic episodes are three times more frequent, and the duration of remission is shortened by an average of 40% compared to non-users. Even when a patient is taking a stabilizer (lithium, valproic acid, lamotrigine), THC can 'bypass' the protection.

In Polish realities, patients with bipolar disorder often do not know about their diagnosis when experimenting with cannabis. The first mania or hypomania can be triggered precisely by THC, and only then is the diagnosis made. If there is a history of bipolar disorder in the family, caution with cannabis must be exceptional, even with "regular" CBD without THC.

What are the symptoms of serotonin syndrome and when to seek help?

Serotonin syndrome is a life-threatening condition requiring immediate intervention. According to the American Heart Association guidelines, full-blown serotonin syndrome has a mortality rate of 2-12% without treatment, but drops below 1% with rapid diagnosis and withdrawal of the serotoninergic drug.

Hunter's triad, or classic symptoms

Diagnosis is based on Hunter's criteria (2003), which have the highest sensitivity and specificity. The patient must be taking a serotonergic drug and present at least one of five symptom sets: spontaneous muscle clonus; induced clonus plus agitation or sweating; ocular clonus plus agitation or sweating; hypertonia plus fever above 38°C plus clonus; tremors plus hyperreflexia.

Additional symptoms include tachycardia above 100/min, dilated pupils, diarrhea, sweating, motor agitation, disorientation, seizures. Symptoms usually appear within 6-24 hours of administering an additional serotoninergic substance, although they can occur after several days with a long half-life of the drug.

Why might CBD and THC increase this risk?

The mechanism is threefold. First, CBD inhibits CYP2C19 and CYP3A4, increasing the concentration of SSRIs. Second, CBD acts as a weak agonist of 5-HT1A, adding serotoninergic signaling independently of SSRIs. Third, some strains of marijuana (especially high in THCV) may modulate serotonin release via the CB2 pathway.

The risk is highest with combinations such as: SSRI + CBD + tramadol; SSRI + CBD + triptan; SSRI + CBD + MDMA; MAOI + CBD. In Polish clinical practice, the most common 'trap' is a patient with migraines, taking escitalopram, reaching for CBD for stress, and adding a triptan during a migraine attack.

What to do if serotonin syndrome is suspected?

First, do not wait. Call emergency medical services at 112 or go to the emergency room. Second, discontinue all serotoninergic medications, including CBD, THC, SSRIs, SNRIs, tramadol. Third, inform the emergency room doctor about all substances taken, including supplements and herbs (St. John's wort also increases the risk).

Hospital treatment includes external cooling, benzodiazepines for agitation, and in more severe cases, cyproheptadine as a serotonin antagonist. Most patients recover within 24-72 hours of discontinuing medications.

How to monitor therapy when a patient uses CBD and antidepressants?

Monitoring is based on four pillars: clinical conversation, measurement of drug levels in the blood (TDM), EKG, and liver function tests. According to AGNP guidelines (Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie) from 2024, therapeutic monitoring of levels is routinely recommended for all patients taking an antidepressant + strong CYP inhibitor, which includes CBD at clinical doses.

When to perform TDM?

TDM (therapeutic drug monitoring) measures the concentration of the drug in serum and allows assessment of whether the patient is within the therapeutic window. The optimal time for sampling is the 'trough level', just before the next dose, usually in the morning. For sertraline, the window is 10-150 ng/ml, for escitalopram 15-80 ng/ml, for citalopram 50-110 ng/ml, for venlafaxine 100-400 ng/ml.

After adding CBD 100 mg/day or more, it is recommended to perform TDM after 2 weeks. If the concentration has risen above the window, the SSRI dose should be reduced by 25-50%, or CBD should be discontinued, depending on the reason for its use. The test is available in Polish university laboratories (e.g., SUM, UM Warsaw, PUM Szczecin) and some private laboratories, costing 100-250 PLN for the measurement.

EKG and QTc interval measurement

Citalopram and escitalopram prolong the QT interval on EKG, especially at doses above 20 mg/day (citalopram) and 10 mg/day (escitalopram). CBD at clinical doses also has a moderate effect on cardiac conduction. Combined use may exceed the clinical threshold (QTc above 500 ms), increasing the risk of ventricular arrhythmias like torsades de pointes.

AHA recommendation for patients combining SSRIs with CBD: perform baseline EKG, after 2 weeks of combined treatment, and then every 3-6 months or after any dose change. With QTc above 470 ms in men and 480 ms in women, a cardiology consultation is required.

Liver function tests

Cannabidiol at high doses (above 300 mg/day) may cause an increase in aminotransferase activity (ALT, AST) above 3x the upper limit of normal. In the FDA program with Epidiolex in children with epilepsy, such an increase was observed in about 16% of patients, reversible after dose reduction. In patients with chronic hepatitis, fatty liver, cirrhosis, evaluations should be more frequent.

Practical recommendation. When adding CBD to an antidepressant, perform baseline liver function tests (ALT, AST, GGT, bilirubin), control after 4 weeks, then every 3-6 months.

What practical recommendations are there for patients in Poland?

Polish realities are specific: medical marijuana has been available by prescription (RPW) since 2017, CBD supplements have been freely available since 2018, and access to TDM in public healthcare is limited. According to a CBOS report from 2023, only 23% of Polish psychiatrists feel confident in their knowledge of cannabis interactions with antidepressants.

Step by step: how to safely consider combining?

For a patient considering combining CBD with an antidepressant, there is a clear path. It protects against most mistakes.

1. Do not discontinue the antidepressant on your own. Even if CBD seems 'more natural', stopping SSRIs abruptly can trigger withdrawal syndrome and a relapse of depression.
2. Schedule an appointment with the treating psychiatrist. Acknowledge which CBD or marijuana products are being used or considered. Without this conversation, treatment selection goes 'blind'.
3. Assess the dose and frequency of CBD. Cosmetic 5-15 mg per day is one thing. Therapeutic 100-600 mg per day is another level of risk.
4. Perform baseline tests. Liver function tests, EKG, possibly TDM of the antidepressant. Cost of several dozen PLN, high diagnostic value.
5. Start with the lowest dose of CBD. 10-25 mg per day, observe for 2 weeks. Only then gradually increase, by 25 mg every 2 weeks, not faster.
6. Keep a diary. Record doses, time of intake, physical symptoms (sedation, nausea, headaches) and mental symptoms (mood, anxiety, sleep). The psychiatrist assesses the trend, not individual days.
7. Monitor every 4-6 weeks. Visit or tele-visit with the psychiatrist. If something is concerning, report it earlier.
8. Never mix with alcohol, tramadol, triptans. These combinations significantly increase the risk of serotonin syndrome.

Choosing safe CBD products

The quality of the CBD product has pharmacological significance. According to the Johns Hopkins report from 2022, 43% of CBD products on the market had cannabidiol content inconsistent with the label, and 26% contained undeclared THC.

Criteria for choosing CBD oil for patients on antidepressants are as follows. Broad-spectrum (without THC) is pharmacokinetically safer than full-spectrum. Certificate of analysis (COA) from an independent laboratory (e.g., Eurofins, ACS Laboratory) confirming CBD content and absence of pesticides. A known brand with a history of cannabis retail. Production date and shelf life. Low THC content (below 0.2%) compliant with Polish law.

Where to seek expert advice?

The first point of contact should be the treating psychiatrist. If they feel unsure about cannabis, it is worth asking for a referral to a center where a clinical pharmacist or medical marijuana clinic operates. In Poland, such clinics operate at several large hospitals and in private practices. A good intermediary source is the Polish Psychiatric Association and the Pharmacotherapy Section.

For patients already interested in flowers, oils, and other cannabinoid products, one of the experienced stores in Poland is the cannabis shop u Bucha, where every product has a laboratory analysis certificate, and the staff does not provide medical advice beyond directing to a doctor.

/cbd-i-fobia-spoleczna-czy-oleje-cbd-moga-pomoc-pozbyc-sie-leku/

Products used in low doses, with low risk of interactions

For patients considering CBD in collaboration with a psychiatrist, it is crucial to choose a product with a known composition, without THC or with minimal content. The following suggestions belong to the broad-spectrum category, meaning they contain cannabinoids that support the entourage effect (CBG, CBC, CBN), but without tetrahydrocannabinol. Each choice should be preceded by the consent of the treating physician.

• SOOL Broad Spectrum CBD 5% (500 mg / 10 ml) – low concentration suitable for individuals starting supplementation, easy titration from 5 mg per drop.
• SOOL Broad Spectrum CBD 10% (1000 mg / 10 ml) – higher concentration for patients who require doses of 50-150 mg per day after psychiatric consultation.
• Cannova CBG 15% (1500 mg / 10 ml) – CBG oil for patients for whom CBD is contraindicated due to strong CYP inhibition. CBG has weaker pharmacokinetic interactions.
• Mars CBD Hemp Herb 9% – CBD flower for vaporization for those who do not tolerate oils. Vaporization at a temperature of 180-200°C.

What alternatives to cannabis exist in the treatment of depression?

Before a patient reaches for CBD or marijuana as an antidepressant support, it is worth knowing the spectrum of recognized, effective alternatives. A meta-analysis by Cipriani et al. in „Lancet” from 2018 compared 21 antidepressants and several non-pharmacological augmentations, which remains the largest study of its kind.

Psychotherapy as the first choice

Cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and acceptance and commitment therapy (ACT) have documented effectiveness comparable to SSRIs in mild and moderate depression. In Poland, the National Health Fund reimburses psychotherapy within mental health clinics, although waiting lists can be long. Privately, the cost ranges from 150 to 250 PLN per session.

Physical activity

A meta-analysis in „BMJ” (2024) involving 218 randomized trials showed that regular moderate-intensity exercise has an antidepressant effect comparable to SSRIs in individuals with mild to moderate depression. Recommendation: 3-5 times a week for 30-60 minutes, any type of activity (walking, jogging, cycling, swimming, yoga).

Light therapy and circadian rhythm regulation

Light therapy lamps (10,000 lux, 30 minutes in the morning) are a first-line treatment for seasonal affective disorder (SAD) and an effective support in non-seasonal depression. Keeping a regular sleep schedule, avoiding screens after 10 PM, and morning exposure to natural light are inexpensive but empirically effective interventions.

Supplements with documented effects

Two supplements have evidence in depression: omega-3 fatty acids (mainly EPA, dose 1-2 g per day) and vitamin D in case of deficiency (dose depending on baseline level of 25(OH)D). Methylfolate and SAMe have evidence in treatment-resistant depression but require psychiatric supervision.

Ketamine and new drugs

Esketamine in nasal spray form (Spravato) and intravenous ketamine have been registered since 2019 for the treatment of resistant depression. The action is rapid, often within hours. In Poland, they are available within drug programs and in some private centers. The cost is high, but for 30% of patients for whom 2-3 SSRIs have not worked, it can be a breakthrough. Psilocybin is in phase III clinical trials, with registration decisions expected in the USA and EU in 2025-2026.

FAQ: frequently asked questions about cannabis and antidepressants

Can I take CBD oil if I am taking sertraline or escitalopram?

Theoretically yes, but only after consulting with a psychiatrist. CBD inhibits CYP2C19 and CYP2D6, which increases the concentration of sertraline and escitalopram by 25-35% (PMC, 2021). At doses of CBD up to 25 mg/day, the effect is usually subtle. Above 100 mg, it is worth considering measuring drug levels in the blood and EKG monitoring.

Is smoking marijuana safe when I take antidepressants?

No. Smoking marijuana simultaneously inhibits the metabolism of some drugs (through CBD in the plant) and induces other pathways (through CYP1A2 from smoke). The effect is difficult to predict. THC may additionally increase anxiety, trigger manic episodes in individuals with bipolar disorder, and disrupt the action of SSRIs at the synapse level. Do not combine without psychiatric consultation.

Can CBD replace antidepressants?

No. Evidence from 5 randomized trials and Cochrane meta-analysis (2023) is of low quality and does not justify replacing SSRIs with cannabidiol. Depression is a life-threatening illness. Discontinuing an antidepressant on your own and switching to CBD can result in a relapse of the episode, suicidal thoughts, and hospitalization.

Does CBD cause serotonin syndrome?

CBD itself at moderate doses is unlikely to, but it increases the risk when combined with SSRIs, SNRIs, tramadol, triptans, MDMA, or St. John's wort. The mechanism is dual: CYP inhibition and weak agonizing of 5-HT1A. The risk mainly concerns high doses (above 300 mg/day) and polypharmacy. Symptoms of serotonin syndrome require urgent medical attention.

Do I have to tell my doctor that I use CBD?

Yes, absolutely. Failing to provide this information is one of the most common causes of unexplained therapeutic failures. According to the report from the Polish Psychiatric Association (2024), only 31% of patients spontaneously inform their psychiatrist about using CBD. Talking to the doctor allows for a safe dose selection and planning monitoring.

Does CBD help with anxiety accompanying depression?

There is evidence for the anxiolytic effect of CBD at doses of 25-600 mg/day (meta-analysis in „Journal of Clinical Medicine”, 2022). In patients with depression and comorbid anxiety, a psychiatrist may, after assessing the risk, approve low doses of CBD as support for SSRI therapy. This requires monitoring and does not replace psychotherapy.

Can THC trigger mania in individuals with bipolar disorder?

Yes. THC triples the risk of a manic episode in individuals with bipolar disorder and shortens the duration of remission by 40% (Harvard Review of Psychiatry, 2020). The risk applies to smoking, vaporizing, and edibles. For individuals with bipolar disorder or its suspicion, cannabis with THC is absolutely contraindicated, even with a mood stabilizer.

What are the safest antidepressants to combine with low-dose CBD?

There are no safe options in the sense of „no risk whatsoever”. Relatively lower pharmacokinetic risk is attributed to bupropion (metabolized by CYP2B6, which CBD affects less) and mirtazapine. However, every combination requires psychiatric consultation, dose adjustment, and monitoring. The decision of “which antidepressant to choose” rests with the psychiatrist, not the patient.

Summary: what to do with this knowledge?

Cannabis and antidepressants are a high-risk pharmacological combination that requires awareness, caution, and psychiatric supervision. Data from 2021-2024 are consistent enough to draw several hard conclusions. First, CBD at therapeutic doses (above 100 mg/day) measurably increases the concentration of sertraline, escitalopram, citalopram, and fluoxetine. Second, THC poses a real recurrent threat in individuals with bipolar disorder or schizophrenia. Third, the combination of SSRIs with CBD, tramadol, and triptans creates a high risk of serotonin syndrome.

What to do about it? First, never discontinue an antidepressant without consulting a psychiatrist, regardless of what CBD advertisements promise. Second, always inform your doctor about taking cannabidiol, even „cosmetic” sublingual drops. Third, choose CBD products with a certificate from an independent laboratory, broad-spectrum, without THC. Fourth, start with the lowest doses, gradually increase, and keep a diary. Fifth, monitor liver function tests, EKG, and, if possible, the concentration of the antidepressant in the blood.

Good pharmacotherapy for depression cannot be left to chance. If CBD can support treatment, it can only be within the conscious collaboration of the patient with the psychiatrist, clinical pharmacist, and primary care physician. Without this trio, any attempt to combine CBD, THC, or cannabis flower with an antidepressant is a risk not worth the benefits.

/cbd-czy-pomaga-w-leczeniu-depresji/

/depresja-jak-konopie-moga-wspomoc-leczenie/

Medical disclaimer. The article is for educational and informational purposes only and does not replace psychiatric or pharmaceutical consultation. Depression is a life-threatening illness that requires professional treatment. Discontinuing or modifying antidepressant therapy on your own can lead to relapse, suicidal thoughts, and hospitalization. CBD products and medical marijuana are not recognized first-line treatments for depression in Poland. During pregnancy, breastfeeding, in individuals under 18 years of age, in patients with bipolar disorder, schizophrenia, severe liver diseases, and those taking MAO inhibitors, cannabis products are contraindicated. If you have suicidal thoughts, call 800 70 2222 (Support Center) or 112.

Author. Michał Waluk, the editorial director of the blog ubucha.pl, specializes in cannabis, cannabinoids, clinical pharmacology, and safe harm reduction. He prepares texts based on peer-reviewed scientific literature (tier 1-3, including PubMed Central, Cochrane, Lancet, JAMA, BMJ, Frontiers in Psychiatry, British Journal of Clinical Pharmacology) and guidelines from regulatory agencies (NICE, EMA, AGNP, Polish Psychiatric Association).